EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of progressive chronic kidney disease on hepatic drug metabolism

Emily D Hartjes, Yong Jin Lim, Thomas J Velenosi, Kait F Al, Jean M Macklaim, Andrew S Kucey, Gregor Reid, Jeremy P Burton, Gregory B Gloor, Bradley L Urquhart

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Emily D Hartjes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonrenal clearance pathways such as drug metabolism are decreased in severe chronic kidney disease (CKD). The impact of progression of CKD on hepatic drug metabolism is unknown. We characterized the effect of progressive CKD on hepatic cytochrome P450 expression and evaluated dysbiosis and uremia as kidney function declined. Rats fed control or CKD-inducing adenine diet were studied at 5 time points over 42 days. Cytochrome P450 expression and activity were compared with alterations in the (1) plasma and liver metabolome and (2) gut bacterial microbiota. CYP3A2 and CYP2C11 were downregulated in CKD by ≥76% (P < .001) concurrently with or slightly prior to CKD onset as defined by serum creatinine. Metabolite profiles were altered prior to changes in the gut microbiota, and gut-derived uremic toxins including indoxyl sulfate, phenyl sulfate, and 4-ethylphenyl sulfate correlated with CYP3A2 or CYP2C11 expression. Bacterial genera Turicibacter and Parabacteroides were identified as being characteristic of CKD. In conclusion, CYP3A2 and CYP2C11 are downregulated before dysbiosis and uremia. SIGNIFICANCE STATEMENT: This study describes the effect of progressive kidney disease on hepatic CYP2C11 and CYP3A2 enzyme expression and activity in a rat model of CKD. Expression and activity of drug metabolizing enzymes occurs prior to uremia or dysbiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicLiverAnimalsRatsMaleGastrointestinal MicrobiomeDysbiosisRats, Sprague-DawleyDisease ProgressionCytochrome P450 Family 2Steroid 16-alpha-HydroxylaseUremiaUremic ToxinsAdenineMetabolomeCytochrome P-450 Enzyme SystemAryl Hydrocarbon Hydroxylases

Stichwörter der Autor:innen

Chronic kidney diseaseDrug metabolismGut microbiomeMetabolomics

Substanzen

Cytochrome P450 Family 2Steroid 16-alpha-HydroxylaseCYP2C11 protein, ratUremic ToxinsAdenineCytochrome P-450 Enzyme SystemAryl Hydrocarbon Hydroxylases

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Microbiology & Immunology, Western University, London, Ontario, Canada; Canadian Centre for Human Microbiome and Probiotics, London, Ontario, Canada.
  • Department of Microbiology & Immunology, Western University, London, Ontario, Canada.
  • Department of Biochemistry, University of Western Ontario, London, Ontario, Canada.
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Division of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistr…

Förderung

  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Hartjes, E. D., Lim, Y. J., Velenosi, T. J., Al, K. F., Macklaim, J. M., Kucey, A. S., Reid, G., Burton, J. P., Gloor, G. B., & Urquhart, B. L. (2025). The impact of progressive chronic kidney disease on hepatic drug metabolism. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100085

Vancouver

Hartjes ED, Lim YJ, Velenosi TJ, Al KF, Macklaim JM, Kucey AS, et al. The impact of progressive chronic kidney disease on hepatic drug metabolism. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100085

BibTeX
@article{Hartjes2025,
  author = {Hartjes, Emily D and Lim, Yong Jin and Velenosi, Thomas J and Al, Kait F and Macklaim, Jean M and Kucey, Andrew S and Reid, Gregor and Burton, Jeremy P and Gloor, Gregory B and Urquhart, Bradley L},
  title = {The impact of progressive chronic kidney disease on hepatic drug metabolism},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100085}
}
Kostenlos starten →